Session 5: Optimizing Initial Therapy of CLL

Co-Chair(s)

• 

  Matthew Davids, MD, MMSc

  Director, Clinical Research, Division of Lymphoma
  Dana-Farber Cancer Institute (DFCI)
  Boston, MA, United States
• 

  Mazyar Shadman, MD, MPH

  Associate Professor of Medicine
  Fred Hutchinson Cancer Center / University of Washington School of Medicine
  Seattle, WA, United States

Presentations:

• 8:15 AM – 8:30 AM EDT

  The Role Today of Continuous BTK Inhibitors
  

  Speaker: Kerry A. Rogers, MD – The Ohio State University
• 8:30 AM – 8:45 AM EDT

  Updated Perspective on Time-Limited Venetoclax + Obintuzumab
  

  Speaker: Othman Al-Sawaf, MD – University Hospital Cologne
• 8:45 AM – 9:00 AM EDT

  Current and Future Use of BTKi + BCL-2i Combinations
  

  Speaker: Nitin Jain, MD – University of Texas MD Anderson Cancer Center
• 9:00 AM – 9:15 AM EDT

  Panel Discussion With Interactivity and Audience Q&A
• 9:15 AM – 9:25 AM EDT

  Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group
  

  Primary Author; Presenting Author: Florian Simon, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Rudy Ligtvoet, PhD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Sandra Robrecht, PhD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Paula Cramer, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Nadine Kutsch, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Moritz Fürstenau, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Valentin Goede, MD – Department of Oncogeriatrics, St. Marien-Hospital

  Co-Author: Julia von Tresckow, MD – Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen

  Co-Author: Petra Langerbeins, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Anna Fink, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Henriette Huber, MD – Städtisches Klinikum Karlsruhe

  Co-Author: Eugen Tausch, MD – Department of Internal Medicine III, Ulm University

  Co-Author: Christof Schneider, MD – Department of Internal Medicine III, Ulm University

  Co-Author: Clemens M. Wendtner, MD – Department of Hematology, Oncology, Immunology, Palliative Care, Munich Clinic Schwabing

  Co-Author: Matthias Ritgen, MD – Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel

  Co-Author: Martin Dreyling, MD – Klinikum der Universität München, Ludwig Maximilian University of Munich

  Co-Author: Lothar Müller, MD – Study Centrum Unter Ems, Practice for Oncology and Hematology

  Co-Author: Lutz Jacobasch, MD – Praxis of Haematology and Oncology

  Co-Author: Werner Heinz, MD – Medical Clinic II, Caritas Hospital Bad Mergentheim, Uhlandstr, 7D-97980

  Co-Author: Ursula Vehling-Kaiser, MD – Praxis für Hämatologie/Onkologie

  Co-Author: Lilly Sivcheva, MD – First Internal Department, MHAT Hristo Botev, AD

  Co-Author: Sebastian Böttcher, MD – Clinic for Internal Medicine III (Hematology, Oncology, Palliative Care), Rostock University Medical School

  Co-Author: Peter Dreger, MD – Department V of Internal Medicine, University Hospital Heidelberg

  Co-Author: Thomas Illmer, MD – Group Practice for Hematology and Oncology

  Co-Author: Michael Gregor, MD – Department of Hematology, Luzerner Kantonsspital

  Co-Author: Philipp Staber, MD – Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna

  Co-Author: Stephan Stilgenbauer, MD, PhD – Department of Internal Medicine III, Ulm University

  Co-Author: Carsten Utoft Niemann, MD, PhD – Department of Hematology, Copenhagen University Hospital Rigshospitalet, Denmark; Hematology Research Group, Danish Cancer Institute Research Center, Denmark; Department of Clinical Medicine, Copenhagen University

  Co-Author: Arnon P. Kater, MD, PhD – Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam

  Co-Author: Kirsten Fischer, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Barbara Eichhorst, MD – University Hospital of Cologne

  Co-Author: Michael Hallek, MD – Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne

  Co-Author: Othman Al-Sawaf, MD – University Hospital Cologne
• 9:25 AM – 9:35 AM EDT

  Minimal residual disease-guided combination of ibrutinib and venetoclax compared to FCR in untreated patients with CLL of intermediate risk : interim results of MRD kinetics in the ERADIC trial from the FILO group
  

  Primary Author; Presenting Author: Anne-Sophie Michallet, MD, PhD – Léon Bérard Cancer Center in Lyon (CLB)

  Co-Author: Anne Quinquenel, MD, PhD – CHU Reims

  Co-Author: Remi Letestu, MD – Laboratoire d'Hématologie, Hôpital Avicenne, APHP

  Co-Author: Magali Legarff-Tavernier, MD – INSERM, UMR-S 945, AP-HP, Hôpital Pitié-Salpêtrière, Service d'Hématologie Biologique

  Co-Author: Fabien Subtil, statisticien – Université de Lyon 1, 69000 Lyon, France; Hospices civils de Lyon, service de biostatistiques

  Co-Author: Thérèse Aurran, MD – Institut Paoli Calmettes

  Co-Author: Kamel Laribi, MD – Hematology Department, Centre Hospitalier du Mans, Le Mans

  Co-Author: Florence Cymbalista, MD, PhD – Hôspital Avicienne

  Co-Author: Vincent Levy, MD, PhD – APHP, Université Sorbonne Paris Nord

  Co-Author: Laurence Simon, MD – Sorbonne Université, Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, Assitance Publique des Hôpitaux de Paris (AP1HP)

  Co-Author: Damien Roos Weill, MD, PhD – Hematology Department, Pitie-Salpetriere Hospital

  Co-Author: Veronique Leblond, MD, PhD – Service Hématologie, Hôpital de la Pitié-Salpêtrière, APHP

  Co-Author: Marie-Sarah Dilhuydy, MD – CHU Bordeaux

  Co-Author: Cecile Tomowiak, MD – Service Hématologie, CHU Poitiers

  Co-Author: Caroline Dartigeas, MD – Department of Haematology, University Hospital of Tours

  Co-Author: Romain Guieze, MD, PhD – Hematology department, Clermont-Ferrand University Hospital

  Co-Author: Olivier Tournilhac, MD, PhD – Hematology department, Clermont-Ferrand University Hospital

  Co-Author: Emmanuelle Ferrant, MD – Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie Clinique

  Co-Author: Sophie de Guibert, MD – CHU Rennes

  Co-Author: Pierre Feugier, MD, PhD – Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risques Environnementaux (N-GERE), Université de Lorraine

  Co-Author: Fatiha Merabet, MD – Department of Hematology and Oncology, Hôpital André Mignot

  Co-Author: Stephane Lepretre, MD – Centre Henri Becquerel

  Co-Author: Philippe Carassou, MD – CHR Metz

  Co-Author: Julie Gay, MD – CH Cote Basque

  Co-Author: Benedicte Hivert, MD – French Innovative Leukemia Organization, 87000

  Co-Author: Luc Matthieu Fornecker, MD, PhD – CHU Strasbourg

  Co-Author: Jehan Dupuis, MD – Lymphoid Malignancies Unit, Hôpital Henri Mondor, AP-HP

  Co-Author: Lysiane Molina, MD – Hématologie clinique, CHU de Grenoble

  Co-Author: Bruno Villemagne, MD – Hematology Department, Centre Hospitalier Départemental

  Co-Author: Guillaume Cartron, MD, PhD – Centre Hospitalier Universitaire de Montpellier

  Co-Author: Bernard Drenou, MD – GHRMSA

  Co-Author: Beatrice Mahe, MD – Chu Nantes

  Co-Author: Omar Benbrahim, MD – Chr Orleans

  Co-Author: Xavier Cahut, MD

  Co-Author: Loic Ysebaert, MD, PhD – IUCT Oncopole

  Co-Author: Florence Nguyen-Khac, MD, PhD – Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière

  Co-Author: Valerie Rouille, MD – CHU Montpellier

  Co-Author: Alain J. Delmer, MD, PhD – Service Hématologie, CHU de Reims
• 9:35 AM – 9:45 AM EDT

  Bruton tyrosine kinase inhibitor ibrutinib induces hypertension by upregulating transcription of CaV1.2 calcium channel
  

  Primary Author: Juejin Wang, MD, PhD – Nanjing Medical University

  Co-Author: Shumin Yin, N/A – Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University

  Co-Author: Feiran Liu, N/A

  Co-Author: Ludan Zhang, N/A

  Co-Author: Xingyu Song, N/A

  Co-Author: Wei Hou, N/A

  Co-Author: Xiaoqing Xiong, PhD – Nanjing Medical University

  Co-Author: Jianyong Li, MD, PhD – Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital

  Primary Author; Presenting Author: Huayuan Zhu, MD – the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
• 9:45 AM – 9:55 AM EDT

  Stopping ibrutinib after 6 years of continuous exposure results in decreased or stable CLL levels for at least a year in most patients, providing further support for the STATIC trial evaluating intermittent BTKi treatment.
  

  Primary Author; Presenting Author: Andy C. Rawstron, PhD – HMDS, Leeds Cancer Centre

  Co-Author: Nichola Webster, N/A – Leeds Institute of Medical Research at St James's, University of Leeds

  Co-Author: David Allsup, MD – Department Hematology, Hull University Teaching Hospitals NHS Trust

  Co-Author: Sue Bell, PhD – Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds

  Co-Author: Adrian Bloor, MD – Christie Hospital NHS Trust

  Co-Author: David Cairns, PhD – Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds

  Co-Author: Anna Hockaday, N/A – Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds

  Co-Author: Sharon Jackson, PhD – Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds

  Co-Author: Surita Dalal, PhD – St. James’s Institute of Oncology

  Co-Author: Ruth de Tute, PhD – HMDS, Leeds Cancer Centre

  Co-Author: Natasha Greatorex, N/A – Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds

  Co-Author: Rhiannon Lambkin, N/A – Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds

  Co-Author: Anita Sarma, MB, ChB – HMDS, Leeds Cancer Centre

  Co-Author: David Stones, N/A – Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds

  Co-Author: Abraham Varghese, MB BS, PhD – Clinical Haematology, Leeds Teaching Hospitals NHS Trust

  Co-Author: Peter Hillmen, MB ChB, PhD – Leeds Institute of Medical Research at St James's, University of Leeds

  Co-Author: Talha Munir, MBBS, PhD – Clinical Haematology, Leeds Teaching Hospitals NHS Trust